Table 2 GO/pathway enrichment analysis on network clusters

Lympho-myeloid

LM1

Chemokine signaling pathway^a

29/31

93.5

6.49e−55

LM2

Antigen processing and presentation^a

6/6

100.0

5.78e−14

LM3

Focal adhesion

31/33

93.9

2.54e−58

LM4

TNF signaling pathway^a

20/41

48.8

3.72e−32

LM5

RIG-I-like receptor signaling pathway^a

7/8

87.5

1.19e−15

LM6

Apoptosis^a

33/65

50.8

2.74e−52

LM7

MAPK signaling pathway^a

44/71

62.0

1.4e−59

LM8

Wnt signaling pathway

13/16

81.2

7.56e−24

LM9

positive regulation of interleukin-8 production^a

6/12

50.0

5.92e−09

LM10

Interleukin-2 family signaling^a

3/3

100.0

2.46e−07

LM11

disulfide oxidoreductase activity^a

4/4

100.0

1.27e−09

Diffuse-myeloid

DM1

Focal adhesion

34/45

75.6

7.1e−57

DM2

PPAR signaling pathway^a

22/28

78.6

1.11e−47

DM3

Dopaminergic synapse^a

23/30

76.7

8.94e−43

DM4

EPHA-mediated growth cone collapse^a

3/3

100.0

3.78e−08

DM5

Cam-PDE 1 activation^a

4/4

100.0

1.41e−13

DM6

Adherens junction^a

5/6

83.3

1.35e−08

Pauci-immune Fibroid

PF1

Focal adhesion

42/45

93.3

2.06e−79

PF2

Ras signaling pathway^a

49/64

76.6

1.09e−79

PF3

Wnt signaling pathway

23/24

95.8

1.2e−12

PF4

Cytokine-cytokine receptor interaction^a

18/18

100.0

4.41e−37

PF5

VEGFR2 mediated vascular permeability^a

4/7

57.1

1.07e−06

PF6

Regulation of RUNX1 Expression and Activity^a

3/3

100.0

1.59e−07

PF7

TGF-beta signaling pathway^a

9/14

64.3

6.25e−17

PF8

mTOR signaling^a

6/6

100.0

7.35e−16

PF9

Adrenergic signaling in cardiomyocytes^a

9/11

81.8

5.71e−16

PF10

Vascular smooth muscle contraction^a

12/19

63.2

2.75e−20

Good Responders

R1

PI3K-Akt signaling pathway^b

34/64

53.1

3.76e−39

R2

ECM-receptor interaction^b

7/7

100.0

2.74e−16

R3

Chemokine receptors bind chemokines^b

6/6

100.0

1.07e−15

R4

MAP2K and MAPK activation^b

5/7

71.4

1.91e−10

R5

disulfide oxidoreductase activity^b

4/4

100.0

1.27e−09

R6

Triglyceride catabolism^b

3/3

100.0

3.77e−08

R7

Cam-PDE 1 activation^b

4/4

100.0

1.41e−13

Non Responders

NR1

Antigen processing and presentation^b

6/6

100.0

5.78e−14

NR2

Chemokine signaling pathway^b

25/25

100.0

1.6e−49

NR3

Wnt signaling pathway^b

23/31

74.2

1.02e−16

NR4

VEGFR2 mediated vascular permeability^b

7/18

38.8

3.12e−14

NR5

Olfactory transduction^b

32/50

64.0

6.9e−10

NR6

RIG-I-like receptor signaling pathway^b

5/6

83.3

4.88e−31

NR7

Platelet activation, signaling and aggregation^b

24/39

61.5

1.34e−17